Psykey, Inc (CEOS) Fair Value & Analysis
Healthcare · US · Market cap $1.7M
Psykey, Inc
CEOS · US
Fair value as of: Jun 26, 2026
From 18 valuation models · updated 7 days ago
Fair value updated Jun 26, 2026 — revised from $0.0700 to $0.0050 (−92.9%) since Jun 24, 2026. Share price −24.2% over the past month.
Price vs Fair Value (12 months)
12‑month range $0.0023 – $0.0120 · fair‑value band $0.0049 – $0.0055 · the $0.0050 price screens above the $0.0050 fair value. As of Jun 26, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Psykey, Inc (CEOS) currently trades at $0.0050, while our model-based Fair Value estimate is $0.0050 — implying the stock looks roughly 0.7% overvalued today. We read business quality at 61/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Key figures & financial health
Figures from reported company fundamentals (EODHD) · as of Jun 26, 2026. TTM = trailing twelve months.
About the company
Psykey, Inc. engages in the research, development, and commercialization of entheogenic, adaptogenic, and nootropic ingredients and formulations for its functional product lines. The company also engages in the development of technologies for the composition, bioavailability, and targeted delivery of entheogen-based therapeutics for the psychedelic market. Its retail products include functional mushroom coffees and teas, oral supplements, and single serve drink mixes. The company was formerly known as CeCors, Inc. and changed its name to Psykey, Inc. in August 2021. The company was incorporated in 2002 and is based in Toronto, Canada.
Revenue & earnings trend
FY2016 – FY2025 · reported fiscal years
Psykey, Inc reported revenue of $6.3M in FY2024 versus $1.5M in FY2016, a compound +19.2%/yr. Reported net income was $3.1M in FY2025.
Is CEOS fairly valued? → Check now
Similar stocks
6 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate (as of Jun 26, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Intuitive Surgical, Inc ISRG | $422.06 | $165.35 | -61% |
| EssilorLuxottica Société anonyme ESLOF | $190.25 | $125.65 | -34% |
| HOYA Corporation HOCPY | $168.16 | $96.16 | -43% |
| Medline Inc MDLN | $36.54 | $30.66 | -16% |
| Becton, Dickinson and Company BDX | $140.71 | $104.17 | -26% |
| Alcon Inc ALC | $65.18 | $44.21 | -32% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Psykey, Inc (CEOS) undervalued?
What is the fair value of CEOS?
What is the quality score of CEOS?
What is the net profit margin of CEOS?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.